HIV Medicine

Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting
pp. 203-212(10)
Authors: Smith Fawzi, MC; Kaaya, SF; Mbwambo, J; Msamanga, GI; Antelman, G; Wei, R; Hunter, DJ; Fawzi, WW

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion
pp. 213-219(7)
Authors: Laurichesse, JJ; Persoz, A; Theodorou, I; Rouzioux, C; Delfraissy, JF; Meyer, L

Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy
pp. 220-225(6)
Authors: van Lunzen, J; Liess, H; Arastéh, K; Walli, R; Daut, B; Schürmann, D

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study
pp. 226-233(8)
Authors: Mallolas, J; Blanco, JL; Labarga, P; Vergara, A; Ocampo, A; Sarasa, M; Arnedo, M; López-Púa, Y; García, J; Juega, J; Guelar, A; Terrón, A; Dalmau, D; García, I; Zárraga, M; Martínez, E; Carné, X; Pumarola, T; Escayola, R; Gatell, JM

Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA
pp. 234-240(7)
Authors: Hill, A; Montaner, J; Smith, C

A double-blind, parallel-group, placebo-controlled, multicentre study of acetyll-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection
pp. 241-250(10)
Authors: Youle, M; Osio, M

Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
pp. 251-258(8)
Authors: Martínez, E; Milinkovic, A; Buira, E; de Lazzari, E; León, A; Larrousse, M; Loncá, M; Laguno, M; Blanco, JL; Mallolas, J; García, F; Miró, JM; Gatell, JM

Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
pp. 259-264(6)
Authors: Hill, A; Moyle, G

Seroprevalence of HIV infection in hospitalized paediatric patients at a tertiary care centre in western India
pp. 265-266(2)
Authors: Shah, I; Katira, B